DNTH 103
Alternative Names: DNTH-103Latest Information Update: 14 Oct 2024
At a glance
- Originator Dianthus Therapeutics
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action Complement C1s inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multifocal motor neuropathy; Myasthenia gravis
- Phase I Autoimmune disorders
Most Recent Events
- 17 Sep 2024 Phase-II clinical trials in Multifocal motor neuropathy (Treatment-experienced) in USA (SC) (NCT06537999)
- 17 Sep 2024 Phase-II clinical trials in Multifocal motor neuropathy (Treatment-experienced) in USA (IV) (NCT06537999)
- 08 Aug 2024 Dianthus Therapeutics plans a phase II Momentum trial for Multifocal Motor Neuropathy (MMN) in August 2024